PCRX vs. OPK, AVIR, ADCT, MCRB, CORT, SUPN, OMER, NKTR, ASMB, and CPIX
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include OPKO Health (OPK), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Seres Therapeutics (MCRB), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
OPKO Health presently has a consensus target price of $2.50, indicating a potential upside of 68.92%. Pacira BioSciences has a consensus target price of $43.60, indicating a potential upside of 117.67%. Given OPKO Health's higher probable upside, analysts plainly believe Pacira BioSciences is more favorable than OPKO Health.
64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 47.3% of OPKO Health shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
OPKO Health has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
Pacira BioSciences received 315 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.84% of users gave Pacira BioSciences an outperform vote while only 65.57% of users gave OPKO Health an outperform vote.
In the previous week, OPKO Health had 9 more articles in the media than Pacira BioSciences. MarketBeat recorded 15 mentions for OPKO Health and 6 mentions for Pacira BioSciences. OPKO Health's average media sentiment score of 0.56 beat Pacira BioSciences' score of 0.49 indicating that Pacira BioSciences is being referred to more favorably in the news media.
Pacira BioSciences has a net margin of 10.34% compared to Pacira BioSciences' net margin of -31.44%. OPKO Health's return on equity of 12.98% beat Pacira BioSciences' return on equity.
Pacira BioSciences has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Pacira BioSciences beats OPKO Health on 13 of the 18 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
